Science & Medicine
BUILD – BREAK – IMPACT
As a freshman at Stanford University, Divya led research projects for novel stem cell therapies at the Stanford Institute for Stem Cell Biology and Regenerative Medicine. She dropped out, at the age of 20, to start Stem Cell Theranostics – a drug screening company that uses disease-specific beating heart cells derived from human skin to perform the first “clinical trial in a dish”.
She quickly realized that lots of cutting-edge medical technologies weren’t making it out of academic institutions due to a fundamental lack of entrepreneurship education for scientists, especially due to difficult commercialization landscapes. To address this problem, Divya founded the first non-profit medical entrepreneurship program for Stanford scientists, StartX Med.
StartX Med has grown to support over 30 healthcare technologies and partners with Stanford Hospital, Johnson & Johnson, and Merck to continue empowering technologists.
Antibody on Human Pluripotent Stem Cells Enables Removing of Teratoma-Forming CellsNature Biotechnology (2011)
In Vivo Directed Differentiation of Pluripotent Stem Cells to Bone and Repair of a Skeletal DefectJournal of Surgical Research (2012)
Human Cardiac Progenitor Cells Engineered with Pim-1 Kinase Enhance Myocardial RepairJournal of American College of Cardiology (2012)
Cell Transplantation and Tissue RegenerationCirculation (2012)
Early Stem Cell Engraftment Predicts Late Cardiac Functional Recovery- Insights from ImagingCirculation: Cardiovascular Imaging (2012)
Clonal Precursor of Bone, Cartilage, and Hematopoietic Niche Stromal CellsProceedings of the National Academy of Sciences (2013)
San Jose Business Journal